12 Results for "

3D spheroid models

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "3D spheroid models" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-156675A
Purity:  99.34%
Plecstatin-1 hydrochloride is a metal complex that drives the aggregation and collapse of the plectin network, and disrupts the cytoskeletal structures of α‑tubulin and F‑actin. Plecstatin-1 hydrochloride triggers oxidative stress, mediates the phosphorylation of eIF2α, and induces molecular features associated with immunogenic cell death, including calreticulin membrane exposure, membrane localization of HSP70/HSP90, ATP secretion, and HMGB‑1 release. Plecstatin-1 hydrochloride induces apoptosis via the intrinsic mitochondrial pathway and exerts anti-invasive activity. Plecstatin-1 hydrochloride inhibits sphere proliferation and reduces clonogenicity in the 3D tumor spheroid model of colon cancer cells. Plecstatin-1 hydrochloride is applicable to relevant research on colorectal cancer .
loading...
    loading...
Cat. No.: HY-148117
CAS No.: 2758431-97-7
Purity:  99.96%
MD13 is a MIF PROTAC degrader with a DC50 of approximately 100 nM. MD13 induces ubiquitination and degradation of MIF by recruiting the Cereblon Cullin RING E3 ubiquitin ligase complex. MD13 inactivates the MAPK pathway and induces G2/M phase cell cycle arrest. MD13 exhibits antiproliferative effects in 3D tumor spheroid models. MD13 can be used in lung cancer-related research .
loading...
    loading...
Cat. No.: HY-175207
CAS No.: 3109469-27-1
Target:  

Glycosidase

Research Areas:  

Cancer

CHI3L1-IN-3 is a CHI3L1 inhibitor. CHI3L1-IN-3 binds to CHI3L1 with Kds of 13.76 μM and 13.5 μM in MST and SPR assays, respectively. CHI3L1-IN-3 demonstrates extended plasma half-lives and microsomal stability, along with reduced intrinsic clearance. CHI3L1-IN-3 induces dose-dependent cytotoxicity, reduces spheroid mass and inhibits migration in a 3D multicellular glioblastoma (GBM) spheroid model. CHI3L1-IN-3 can be used for the study of GBM .
loading...
    loading...
Cat. No.: HY-156675
CAS No.: 2119725-22-1
Plecstatin‑1 is a metal complex that drives the aggregation and collapse of the plectin network, and disrupts the cytoskeletal structures of α‑tubulin and F‑actin. Plecstatin-1 triggers oxidative stress, mediates the phosphorylation of eIF2α, and induces molecular features associated with immunogenic cell death, including calreticulin membrane exposure, membrane localization of HSP70/HSP90, ATP secretion, and HMGB‑1 release. Plecstatin-1 induces apoptosis via the intrinsic mitochondrial pathway and exerts anti-invasive activity. Plecstatin‑1 inhibits sphere proliferation and reduces clonogenicity in the 3D tumor spheroid model of colon cancer cells. Plecstatin-1 is applicable to relevant research on colorectal cancer .
loading...
    loading...
Cat. No.: HY-181306
CAS No.: 2653338-61-3
Research Areas:  

Cancer

PROTAC EZH2 Degrader-11 (compound 2) is a EZH2-targeting PROTAC protein degrader. PROTAC EZH2 Degrader-11 reduces tumor size and viability in 3D spheroid models. PROTAC EZH2 Degrader-11 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-D3114
Target:  

Fluorescent Dye

Research Areas:  

Others

FlCFe1 is a ratiometric ferrous ion probe that enables imaging of iron distribution in 3D cell models such as tumor spheroids. Its detection mechanism relies on its structure as a ratiometric analog of calcein AM. It has an excitation wavelength of 405 nm, with emission wavelengths of 490 nm (coumarin emission signal) and 530 nm (fluorescein emission signal) .
loading...
    loading...
Cat. No.: HY-161811
Research Areas:  

Cancer

FEACYP is a thioredoxin reductase (TrxR) inhibitor. FEACYP inhibits thioredoxin reductase activity, induces ROS by increasing basal cellular hydrogen peroxide production, suppresses tumor growth, exerts cytotoxicity against human cancer cells, and exhibits antiproliferative activity in human pancreatic cancer 3D spheroids. FEACYP can be used in the research of ovarian cancer, colon cancer, pancreatic cancer, and lung cancer .
loading...
    loading...
Cat. No.: HY-187511
CAS No.: 3133892-41-5
Target:  

STAT HDAC

Research Areas:  

Cancer

NS06 is a dual-target inhibitor of STAT3 and HDAC, with a Kd of 5.82 μM for human STAT3, an IC50 of 129.1 nM for human HDAC1, an IC50 of 451.2 nM for human HDAC3, and an IC50 of 230.4 nM for human HDAC6. NS06 binds to STAT3 to inhibit its phosphorylation without altering the total STAT3 level; it inhibits the enzymatic activity of HDAC via coordination with Zn 2+ at the catalytic center of HDAC1 and increases the acetylation level of histone H3. NS06 induces cell apoptosis, inhibits cancer cell migration and colony formation, and exhibits antiproliferative activity against solid tumor cells and 3D tumor spheroid models. NS06 is applicable to solid tumor-related research .
loading...
    loading...
Cat. No.: HY-185743
ZW-191 is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα). ZW-191 consists of ZW-191 Antibody (HY-P992515) as the antibody component and MC-GGFG-AM-(10Me-11F-Camptothecin) (HY-153360) as the linker-payload component. ZW-191 possesses excellent tumor sphere penetration, cellular internalization and payload delivery capabilities, and can release a topoisomerase 1 inhibitor inside tumor cells to inhibit tumor cell activity. ZW-191 exerts a potent bystander effect on both antigen-positive and antigen-negative cells. ZW-191 exhibits prominent activity in xenograft models of cell lines with different FRα expression levels. ZW-191 can be used in studies related to ovarian cancer, non-small cell lung cancer, endometrial cancer and triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-P992515

Research Areas:  

Cancer

ZW-191 Antibody is a humanized IgG1 antibody targeting folate receptor α (FRα). ZW-191 Antibody is conjugated with MC-GGFG-AM-(10Me-11F-Camptothecin) (HY-153360) to generate the antibody-drug conjugate (ADC) ZW-191 (HY-185743). ZW-191 Antibody-based ADC exerts a potent bystander effect on both antigen-positive and antigen-negative cells. ZW-191 Antibody is applicable to research related to ovarian cancer, non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-181350
CAIX/XII/NAMPT-IN-1 is a triple inhibitor of carbonic anhydrase IX/XII and nicotinamide phosphoribosyltransferase (NAMPT) with a hCA IX Ki of 78.1 nM, hCA XII Ki of 64.4 nM, and hNAMPT IC50 of 168 nM. CAIX/XII/NAMPT-IN-1 induces apoptosis, ROS accumulation, suppresses ERK/AKT signaling, inhibits DNA synthesis, and causes mitochondrial dysfunction. CAIX/XII/NAMPT-IN-1 exerts antiproliferative effects against multiple cancer cells under normoxic and hypoxic conditions. CAIX/XII/NAMPT-IN-1 can be used for the research of cancer, such as renal carcinoma, glioblastoma and colorectal cancer .
loading...
    loading...
Cat. No.: HY-181559S
Synonyms: AG06827
Target:  

mAChR

Research Areas:  

Neurological Disease

VU6025733 (AG06827) is a highly selective, orally active and blood-brain barrier-penetrant positive allosteric modulator of the muscarinic acetylcholine receptor subtype M4 (M4 mAChR). VU6025733 exerts a potentiating effect on acetylcholine-induced receptor activation with an EC50 of 23 nM for hM4 and 55 nM for rM4. VU6025733 shows high selectivity over other muscarinic acetylcholine receptor subtypes, dose-dependently reduces amphetamine-induced hyperlocomotion in rats. VU6025733 is applicable to the research of schizophrenia, Parkinson's disease, and Alzheimer's disease .
loading...
    loading...
  • 1